// App-Quantinova.ai

2668 : Immune Cell Phenotype and Function After Treatment With Blinatumomab For Childhood Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Researchers

Presenter

  • Alice Bertaina

Principal Investigators

  • Perla Filippini

  • Valentina Bertaina

  • Barbarella Lucarelli

  • Aurelie Bauquet

  • Gerhard Zugmaier

  • Franco Locatelli

  • Sergio Rutella

Medical Centers

  • Pediatric Hematology/Oncology and Transfusion Medicine, IRCCS Bambino Ges Childrens Hospital, Rome, Italy

  • University of Pavia, Pavia, Italy

  • Pediatric Hematology/Oncology, IRCCS Bambino Ges Childrens Hospital Rome, University of Pavia, Rome, Italy

Locations

  • Italy

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 31

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Protein Tyrosine Phosphatase, Receptor Type C

  • Interleukin 17A

  • Interleukin 4

  • T helper 2

  • Type 1 T helper

Drug/Treatment

  • Phorbol myristate acetate

  • Blinatumomab

  • Interleukin

  • Interferon

  • lonomycin

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved